The first phase 3 readout with Spine BioPharma's drug candidate for chronic low back pain (CLBP) has proved disappointing, but the company still believes there is a way forward for the programme. The ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果